Pregled bibliografske jedinice broj: 597917
PCR and Immunophenotyping Samples of Lymph Node and Bone Marrow
PCR and Immunophenotyping Samples of Lymph Node and Bone Marrow // Cytopathology Volumen 23 Supplement 1 / Herbert, A ; Cochand-Priollet, B (ur.).
Oxford: Wiley-Blackwell, 2012. str. 14-14 (pozvano predavanje, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 597917 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
PCR and Immunophenotyping Samples of Lymph Node and Bone Marrow
Autori
Kardum Paro, Mirjana Mariana ; Šiftar, Zoran ; Flegar-Meštrić, Zlata ; Kardum-Skelin, Ika ; Jelić Puškarić, Biljana ; Ostojić Kolonić, Slobodanka.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Cytopathology Volumen 23 Supplement 1
/ Herbert, A ; Cochand-Priollet, B - Oxford : Wiley-Blackwell, 2012, 14-14
Skup
37th European Congress of Cytology
Mjesto i datum
Cavtat, Hrvatska; Dubrovnik, Hrvatska, 30.09.2012. - 03.10.2012
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
PCR; immunophenotyping; samples
Sažetak
Fine needle aspirates (FNAs) of lymph node and bone marrow (BM) aspirates are widely used in clinical cytopathology for diagnosis of lymphoma. Additional methods such as polymerase chain reaction (PCR) and flow cytometry immunophenotyping (FCI) can complement present cytological and immunological methods and help to overcome problems raised from the amount and quality of LN and BM samples. Therefore it is advisable to process them within 24 hours of receipt. Today, methods like nested PCR for detection of fusion genes or multiplex PCR for detection of monoclonal rearrangements of the immunoglobulin or T cell receptor genes have proved to be a valuable marker for malignancy in haematological disorders. Although this techniques are simple, they have however a number of limitations: sufficient number of lymphocytes must be obtained, contamination must be avoid, the neoplastic population must comprise 10% or more of the total population and the gene rearrangement of the neoplastic cell clone must be amplifiable by the consensus primers used. Therefore all FNAs and BM aspirates are routinely processed in duplicate to place more weight on the detection and presence rather than absence of a monoclonal band. FCI as a fast, objective and quantitative multiparametric method has become the preferred method for the lineage assignment, detection of clonality and aberrant antigen coexpression, as well as for quantitation of malignant cells based on the determination of various cell differentiation (CD) markers. It can also detect monoclonal B- cell populations that by cytomorphology may be interpreted as reactive. FCI sample preparation must consider the type of specimen submitted and the number of cells available for analysis. FCI usually performed, but not limited, on routine specimens such as peripheral blood (PB) or BM aspirates which should be processed to contain cell suspension at a concentration optimal for monoclonal staining. Paradoxically, cytological specimens such as FNAs of lymph node which are already cell suspensions are rarely used for FCI. A single cell suspension preparation is crucial. Over the years, FCI standardization has lead to improvements in its performing. In attempts to assist with FCI standardization, the United States–Canadian Consensus and The National Committee for Clinical Laboratory Standards (NCCLS) guidelines provided recommendations for FCI in hematopathology, but each laboratory is still ultimately responsible for validating its own measuring instrument, the reagents and the procedures. Today, for an objective and useful interpretation of FCI of FNAs of lymph node it is necessary to obtain the ideal number of 10 000 cells in a tube and to avoid selective cells loss during the cell preparation process. Proposed analytical protocols and procedures also must be used to rule out the most common sources of variability and to ensure proper analytical result.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081873-1893 - Prognostički faktori, dijagnostika i terapija hemoblastoza (Jakšić, Branimir, MZOS ) ( CroRIS)
198-1980955-0953 - Imunobiologija kronične B-limfocitne leukemije i mikrookoliš (Jakšić, Ozren, MZOS ) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb,
Medicinski fakultet, Split,
Akademija medicinskih znanosti
Profili:
Ika Kardum-Skelin
(autor)
Zoran Šiftar
(autor)
Mirjana Mariana Kardum-Paro
(autor)
Slobodanka Ostojić Kolonić
(autor)
Biljana Jelić Puškarić
(autor)
Zlata Flegar-Meštrić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE